RxDoctor Payments Data

Geoffrey Rodriguez, MD

Ophthalmology · Cambria Heights, NYNPI 1770939456

Payments from drug & device makers

$3,652in general payments, 2019–2025

Across 70 payments — averaging $52.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$745
  • Alcon$728
  • Oyster Point Pharma, Inc.$637
  • Sight Sciences, Inc.$351
  • AbbVie$299
  • Sun Pharmaceutical Industries Inc.$255
  • plus $636 from 8 others

What the payments were for

  • Food & beverage$3,652100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,652 in reported general payments places this provider in the 70th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$363,396
Medicare patients
612
Services billed
2,569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost87$39,732
XiidraLifitegrast34$27,687
RestasisCyclosporine18$25,080
LumiganBimatoprost44$23,180
CequaCyclosporine11$13,300
Prednisolone Acetate198$9,138
Restasis MultidoseCyclosporine14$9,043
CombiganBrimonidine Tartrate/Timolol15$8,146
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol50$7,256
SimbrinzaBrinzolamide/Brimonidine Tart17$4,537
Cyclosporine16$4,424
Travoprost28$4,264
Brimonidine Tartrate122$4,052
Ketorolac Tromethamine183$3,851
Latanoprost408$3,747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Restasis Multidose, Combigan$299$65,44991 claims
Aerie Pharmaceuticals, Inc.Rocklatan$63$39,73287 claims
Bausch & Lomb Americas Inc.Xiidra$116$27,68734 claims
Sun Pharmaceutical Industries Inc.Cequa$255$13,30011 claims
AlconSimbrinza$728$4,53717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Cambria Heights

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →